Application value of the Influenza A Virus Antigen Detection Kit (Magnetic Particle Chemiluminescence Method) in clinical diagnosis and influenza prevention and control

Addressing the demand for rapid outpatient screening during influenza season

During influenza epidemics, fever clinics and pediatric emergency departments often face a large number of patients with influenza-like symptoms. The influenza A virus antigen detection kit (magnetic particle chemiluminescence method), with its 30-60 minute detection turnaround time, can complete testing and produce results within the patient's waiting period. Compared with the traditional colloidal gold method, this method requires no manual interpretation, and the instrument automatically outputs numerical values, effectively avoiding missed detection caused by difficulty in identifying weak positive bands. At the same time, its relatively high negative predictive value helps rule out influenza A virus infection, reduces unnecessary antiviral drug use and isolation time, and optimizes the allocation of medical resources.

Assisting in the etiological diagnosis of hospitalized patients and severe cases

For suspected influenza patients requiring hospitalization, especially children, the elderly, and high-risk populations with underlying diseases, the influenza A virus antigen detection kit (magnetic particle chemiluminescence method) can serve as a rapid screening tool. Although nucleic acid testing remains the gold standard, the rapidity of the chemiluminescence method helps initiate antiviral treatment early (such as oseltamivir) and implement contact isolation measures. Some studies have shown that the magnetic particle chemiluminescence method can achieve a sensitivity of 85%-95% within 3 days of onset, with good consistency with nucleic acid testing. It is worth noting that for immunocompromised patients or samples collected more than 5 days after onset, viral load may decrease, and nucleic acid testing should be used in conjunction for confirmation.

Role in influenza surveillance and public health prevention and control

In the influenza surveillance network, CDCs and sentinel hospitals need to collect etiological data in large quantities and continuously. The influenza A virus antigen detection kit (magnetic particle chemiluminescence method) can rely on fully automated chemiluminescence immunoassay analyzers to achieve batch testing, with a single instrument processing 100-200 samples per hour, making it suitable for specimen throughput during influenza season. Its digital results facilitate integration with laboratory information systems, enabling real-time reporting and trend analysis. In addition, this kit can also play a role in mobile testing scenarios during influenza outbreak events (such as schools and nursing homes). Equipped with a portable luminescence analyzer, it can quickly complete screening and assist epidemiological investigation and prevention and control decisions.

Hospital infection prevention and control and patient triage management

In the emergency department or respiratory department of a general hospital, rapidly distinguishing patients with influenza A from those without influenza helps with reasonable zoning and placement, reducing the risk of nosocomial cross-infection. As a clinical auxiliary diagnostic tool, the influenza A virus antigen detection kit (magnetic particle chemiluminescence method) can support the clinical initiation of standard precautions and antiviral treatment when the result is positive, while negative results need to be comprehensively judged in combination with clinical symptoms and other testing indicators. It should be emphasized that any detection method carries the risk of false negatives and false positives, and physicians should reasonably interpret results in combination with local epidemiological characteristics and the patient's disease course. During the use of the kit, the laboratory should establish internal quality control procedures and regularly participate in external quality assessment to ensure the reliability of results.